Trial Profile
Double-blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Two Infusions Four Weeks Apart of Interleukin-6-Receptor Inhibitor (Tocilizumab) on Pain Relief in Patients With Severe Osteoarthritis of the Hand Refractory to Usual Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms TIDOA
- 29 Jul 2019 Status changed from recruiting to completed.
- 04 Sep 2017 Planned number of patients changed from 90 to 110.
- 04 Sep 2017 Planned End Date changed from 1 Sep 2017 to 20 Feb 2019.